Skip to Content Skip to Search

We are a science-led global healthcare company. Our purpose is to help people do more, feel better, live longer.

Research & Development

Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients

We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our Pharmaceuticals research is focused on science related to the immune system, the use of human genetics, and the application of advanced technologies such as functional genomics, artificial intelligence and machine learning. Our approach is driven by the “multiplier effect” of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritising those molecules with a higher probability of success and terminating less promising programmes. It also enables us to increase our focus on specialty medicines in areas such as oncology.

In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.

Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more

Key facts

  • 12,000+

    Over 12,000 people working across our three global businesses

  • £4.6bn

    Our adjusted R&D investment in 2020

  • 57

    Our pipeline comprises 57 vaccines and medicines in development at FY 2020

Sharing Our Research

Graduates can join us in a variety of exciting roles across several business functions.

Clinical Trial Phase

Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer. You can also access all the data from our trials in our Clinical Study Register.

Throughout each trial, the proceedings are monitored by government authorities as well as GSK’s own Global Safety Board (GSB).

There are always at least three phases to clinical trials. Occasionally a fourth phase might be necessary if:

  • we think the medicine can be improved
  • we need to provide answers to questions from the regulatory authorities

Phase I

The first time a new treatment or vaccine is tested in humans, it will usually be given to a small group of healthy volunteers. However in some cases – such as when a new medicine is being tested as a treatment for a terminal illness like cancer - it may be tested on volunteers who have the condition.

The principle objectives in phase I are to:

  • make sure that the new medicine presents no major safety issues
  • clarify that it can reach the targeted body area, and remain there long enough to deliver its benefits
  • gain preliminary evidence that it could offer therapeutic value, or prevent the disease or condition

Phase II

If phase I is successful, approval will be sought for a trial involving a larger group of people. phase II trials will usually (but not always) include patients who have the condition the potential medicine is targeting, and aim to establish:

  • effectiveness in treating the condition
  • effectiveness in preventing the condition (if the volunteer does not already have it)
  • appropriate dosing levels

At this stage, the performance of the medicine may be compared against a group of patients receiving a placebo. A placebo is a treatment that looks the same as the potential new medicine, but has no active ingredients.

In this way a reference group is established against which the performance of the new medicine can be judged. It is important that neither the patients nor the researchers have any idea which volunteers receive which treatment. This is known as double blind placebo control, and ensures there can be no bias in the reporting of the results.

Phase III

If the results from phase II are encouraging, we will seek to start a phase III trial. This will be a much larger trial, often involving hundreds, possibly thousands of participants coming from a range of different countries.  

The principle objectives in phase III are to:

  • demonstrate the safety and effectiveness of the new medicine or vaccine in the typical patient likely to use it
  • confirm effective dosing levels
  • identify side effects or reasons why the treatment should not be given to people with the condition in question (known as ‘contraindications’)
  • build knowledge of the benefits of the medicine or vaccine and compare them with any risks
  • compare results against any currently achieved by existing treatments

To be a success today, a new medicine usually needs to offer the prospect of better treatment for patients than any treatments that are already available.

Phase III trials may last several years. If a new medicine or vaccine completes phase III with positive results, we may seek regulatory approval to make it available in a range of countries or regions.

In the case of a new medicine, regulators will determine how it should be used, and which patients should qualify for it, based on all the evidence from clinical and pre-clinical studies. This is known as a medicine’s indication.

Monitoring medicines after launch

Monitoring is overseen by our Global Safety Board (GSB), which is chaired by our chief medical officer and made up of senior physicians and scientists.

Part of its remit is to review the information on the safety of our products as reports come in from patients and prescribers on the use of the medicines.

All the board's decisions are guided by the need to ensure that the benefits of our medicines and vaccines always outweigh any risks. We continue to monitor patients' responses to our medicines through reports and regulator reporting systems. We follow this information to understand fully a new medicine's effectiveness. We also look for any adverse effects that may only become apparent as more patients use a treatment.

Patient-level data

The patient-level data request site is a system which allows researchers to examine the study details more closely, do their own analyses and learn more about medicines and how they can best be used.

Consistent with good scientific practice, researchers will be required to submit a research plan and to commit to transparency in the publication of their work.


Find out more about our global R&D

Read more about our global focus areas, use of animals and partnerships on our global website.